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Recent developments have increased the options for 
treatment of viral infections. Vidarabine, an agent orig­
inally released for herpes simplex encephalitis, has more 
recently been shown to be of benefit in neonatal herpes 
simplex infection and in varicella-zoster infections in 
immunocompromised hosts. The introduction of acyclo­
vir represents a major advance in antiviral therapy 
because of its low host toxicity and marked selectivity 
for herpes simplex and varicella-zoster viruses. Exten­
sive controlled clinical trials demonstrate efficacy in the 
treatment of infections caused by these viruses in the 
immunocompromised host and in genital herpes simplex 
infections in normal hosts. The use of recombinant DNA 
technology has increased the purity, variety, and avail­
ability of interferons for clinical trial. Earlier experi­
ence with natural buffy coat-derived alpha interferon 
showed efficacy in the treatment of varicella-zoster in­
fections in the immunocompromised host, as well as 
prophylaxis of herpes virus infections in high-risk pop­
ulations. These results have to be confirmed using the 
newer interferon preparations. Under development are 
a variety of new drugs with broadened viral spectrum 
and improved pharmacokinetic properties. These in­
clude nucleoside analogues and novel interferons with 
modified amino acid sequences. One or more of these 
agents, used singly or in combination, may prove useful 
in the more difficult therapeutic problems, such as cy­
tomegalovirus and hepatitis B infections. 
Effective antiviral therapy began in the 19605 with the intro­
duction of topical idoxuridine for the treatment of herpes 
simplex keratitis. Later in that decade, amantadine was intro­
duced for the prophylaxis and therapy of influenza A infections. 
In the early 1970s, case reports of success in the treatment of 
systemic herpesvirus infections with intravenous idoxuridine 
or cytosine arabinoside could not be confirmed in controlled 
trials; these drugs demonstrated unacceptable toxicity, and this 
resulted in considerable disillusionment with antiviral therapy 
in general. Remarkable progress has since occurred, Drugs with 
greater antiviral specificity are now available. Antiviral t.rials 
have become more sophisticated as a result of better under­
standing of the natural history of the target infections, use of 
laboratory methods for virologic confirmation of diagnoses 
prior to therapy, and the widespread acceptance of properly 
randomized controlled trials as a requirement for establishing 
efficacy. 
Vidarabine and acyclovir have been released for the intra­
venous therapy of some herpesvirus infections after successful 
multicenter collaborative trials. Much experience has also been 
gained in the use of exogenous interferon. Although most large-
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scale antiviral clinical trials so far have focused on herpesvirus 
infections, the therapy of respiratory viral infections and viral 
hepatitis are also areas of active investigation. Results of some 
recent controlled trials will now be reviewed and the prospects 
for further development discussed. 
VIDARABINE 
The nucleoside analogue vidarabine (adenine arabinoside) is 
active against a number of DNA viruses. The viral DNA poly· 
merase is inhibited, more so than the corresponding host en­
zyme, Although much less toxic than idoxuridine or cytosine 
arabinoside, vidarabine still has some significant adverse ef­
fects, such as bone marrow suppression, neurotoxicity, and 
mutagenicity. This limits the systemic use of vidarabine to 
serious or life-threatening viral infections (Table I). It is given 
intravenously in dilute solution because of its low water solu­
bility; the more soluble monophosphate derivative that can be 
given intramuscularly is under study, Topical vidarabine is 
available for the treatment of herpes simplex epithelial kerati­
tis. 
Herpes Simplex Encephalitis 
Initially, vidarabine was released solely for use in herpes 
simplex encephalitis [1], a condition in which the drug de­
creased mortality from 70 to 40%, although serious residual 
morbidity in the survivors makes this therapy far from ideaL 
Patients comatose at the time of initiation of vidarabine do not 
seem to benefit significantly, and it is likely that the amount 
of brain destruction that has occurred at this stage is irrever­
sible, Best results are obtained with early specific diagnosis and 
rapid institution of therapy, a theme that has been reinforced 
by experience in the treatment of many other viral infections , 
Unfortunately, the reliable noninvasive early diagnosis of her­
pes simplex encephalitis has yet to be achieved. 
Neonatal Herpes Simplex Infections 
Vidarabine has more recently been approved for the treat­
ment of neonatal disseminated herpes simplex infection, which, 
like herpes simplex encephalitis, is a devastating illness with 
high mortality and residual morbidity, In this setting, a con­
trolled clinical trial [2] demonstrated a reduction in mortality 
in disseminated disease from 85 to 57%, and in encephalitis 
from 50 to 10%, but most survivors had major sequelae at 1 
year follow-up, despite therapy, The situation is thus similar 
to that with herpes encephalitis in adults. 
Varicella-Zoster Infections 
Varicella-zoster infections are mild in normal hosts but cause 
severe morbidity and occasional mortality in patients with 
abnormal cellular immune mechanisms, Multicenter random­
ized trials of vidarabine therapy in these immunocompromised 
hosts have been conducted over a several-year period. All 
patients in the more recent trials had to be entered within 72 
h of onset of varicella or herpes zoster. In varicella [3], vidar­
abine significantly reduced the duration of new lesion formation 
and the incidence of visceral complications; the numbers were 
too small to measure an impact on mortality . In herpes zoster 
[4], vidarabine reduced new lesion formation in the primary 
dermatome and reduced the incidence of cutaneous dissemi-
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TABLE 1. Indications for intral'enous vidarabine 
Herpes simplex encephalitisa 
Neonatal central nervous system and disseminated herpes simplex 
infectiona 
Varicella or herpes zoster in immunocompromised hosts 
a Approved by the U.S. Food and Drug Administration for these 
indications. 
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FIG 1. Mechanism of action of acyclovir. 
nation (from 24 to 8%) and visceral dissemination (from 19 to 
5%). One of the major goals in therapy of herpes zoster is the 
prevention of postherpetic neuralgia. In the vidarabine trial, 
the incidence of neuralgia was the same (45%) in both vidara­
bine and placebo recipients, but the duration of the neuralgia 
was significantly shorter in the vidarabine recipients, as meas­
ured by the percentage of patients free of pain at 4 months (17 
vs56%). 
ACYCLOVIR 
The recently released nucleoside analogue acyclovir is the 
prototype of a new class of agents with high specificity for 
herpes simplex and varicella-zoster viruses because of selective 
phosphorylation of the drug by a virus-specified thymidine 
kinase enzyme (Fig 1). Host cell enzymes are much less effective 
at phosphorylating acyclovir itself, but are capable of convert­
ing acyclovir monophosphate to the triphosphate, which is the 
active drug. Acyclovir triphosphate inhibits viral replication by 
inhibiting the viral DNA polymerase. Viral specificity is in fact 
achieved in two ways: The active drug is made largely in 
infected cells where the viral thymidine kinase is present, and 
the active triphosphate compound inhibits the viral DNA po­
lymerase more than the cellular alpha DNA polymerase [5]. 
Thus it is not surprising that herpes simplex type 1 is inhibited 
at concentrations of acyclovir one thousand times less than 
those which inhibit host cell proliferation. Herpes simplex type 
2 and varicella-zoster viruses are 10- to 30-fold less sensitive 
than herpes simplex type 1, but they are well within the reach 
of clinically achievable drug concentrations. Cytomegalovirus 
and Epstein-Barr virus, which do not encode their own thymi­
dine kinase enzyme, are much less sensitive to acyclovir, and 
the clinical efficacy of the drug against these viruses is doubtful. 
Strains of herpes simplex and varicella-zoster resistant to 
acyclovir have been noted among wild isolates and from pa­
tients receiving acyclovir; these strains either lack thymidine 
kinase activity or have an altered DNA polymerase [6]. The 
characteristics of disease due to resistant viral strains has yet 
to be determined; in some cases, the resistant strains of herpes 
simplex appeared to have less virulence in animal models [7]. 
The development of drug resistance to new antiviral agents can 
be anticipated, by analogy to the experience with antibiotics, 
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and must be continually watched for as these drugs come into 
more widespread use. 
Clinical experience so far indicates that acyclovir is relatively 
nontoxic. It is available in intravenous and topical forms; an 
oral version is currently experimental. An ophthalmic ointment 
is effective in herpes simplex (epithelial) keratitis, but it is not 
available in the United States. The drug is mainly excreted 
unchanged by the kidneys; when high blood levels exist in 
conjunction with low urine output, the drug can crystallize in 
the renal tubules and cause renal function impairment. With 
care to adjust dosages for renal function impairment and main­
tenance of adequate hydration, nephrotoxicity can be avoided. 
Occasional patients developed reversible neurotoxicity while 
receiving the drug. Bone marrow toxicity is not observed with 
therapeutic levels of acyclovir. Current indications are listed in 
Table II. 
Herpes Simplex Infections in Immunocompromised Hosts 
Perhaps the most impressive therapeutic effect of acyclovir 
therapy is on progressive mucocutaneous herpes simplex infec­
tions in immunocompromised hosts. For example, recipients of 
organ transplants often develop reactivation herpes simplex 
stomatitis, which if untreated causes painful ulcerative lesions 
that persist for several weeks and can result in complications 
such as esophagitis and tracheobronchitis. In a controlled mul­
ticenter trial [8], intravenous acyclovir therapy resulted in a 
highly significant shortening of the duration of viral shedding 
and a significant clinical benefit in terms of lesion pain, scab­
bing, and healing. Typically, viral replication can be halted 
within a few days after starting therapy, and healing occurs in 
1 or 2 weeks. Also, prophylactic administration of intravenous 
acyclovir was able to prevent the occurrence of herpes simplex 
viral shedding and clinical reactivation in bone marrow trans­
plant patients [9]. Preliminary data indicate that oral acyclovir 
can be substituted fo� the intravenous drug for these indica­
tions. The topical form may be considered for more limited 
cutaneous lesions. An important observation is that acyclovir 
is only able to inhibit active herpes simplex infection; the 
ganglionic latent state of the virus is unaffected, and recurrent 
episodes of disease are not prevented. 
Genital Herpes Simplex Infections 
Although effective therapy for genital herpes simplex infec­
tions has long been sought, most of the proposed treatments 
have been ineffective in controlled trials. Acyclovir is the first 
antiviral agent of proven efficacy in genital herpes simplex 
infections, but substantial clinical benefit is observed only in 
primary genital herpes, where the severity of untreated disease 
is greater because of lack of previous exposure to the virus. 
Therapy is most often sought for recurrent genital herpes; these 
episodes typically have a short natural duration of viral repli­
cation, and the opportunity for antiviral therapy to have a 
clinical impact is limited. What patients really want is "cure," 
i.e., cessation of further recurrent episodes, and no presently 
known antiviral agent can accomplish this. 
Controlled trials with intravenous [10], oral [11], and topical 
[12] acyclovir in primary genital herpes all indicate that therapy 
can reduce the duration of viral shedding, symptoms, and time 
to healing by several days in this condition. The incidence of 
subsequent recurrent episodes does not seem to be affected. In 
recurrent disease, acyclovir given orally [13] or topically [12] 
TABLE II. Indications for acyclovir 
Mucocutaneous herpes simplex infection in immunocompromised 
hosts" 
Primary genital herpes simplex infections" 
Varicella-zoster infections in immunocompromised hosts (i.v.) 
a Topical and intravenous forms are approved by the U.S. Food and 
Drug Administration for these indications. 
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reduced the duration of viral shedding by about 1 day; a 
corresponding reduction in healing time was statistically de­
monstrable but of uncertain importance in clinical practice. 
Varicella-Zoster Infections 
Multicenter controlled trials were conducted with acyclovir 
in the therapy of varicella-zoster infections in immunocom­
promised hosts. The varicella trial [14] had a small study 
sample, and furthermore, some of the placebo recipients were 
switched to acyclovir in midstudy, thus obscuring the interpre­
tation of the differences between the treatment groups. No 
statistically significant difference in healing times could there­
fore be demonstrated, but none of 7 acyclovir recipients devel­
oped pneumonitis after entry, as opposed to 5 of 11 placebo 
recipients. In herpes zoster [15], patients receiving acyclovir 
within :1 days of onset of lesions had less progression of disease 
in the primary dermatome and less cutaneous and visceral 
dissemination, a combination of findings also found with vi­
darabine and interferon. In contrast to the findings with the 
latter two drugs, however, it was not possible to demonstrate 
an effect of acyclovir on postherpetic neuralgia. Whether this 
represents a real difference between acyclovir and the other 
drugs is unclear because of differences in the conduct of the 
various studies. Patients receiving acyclovir more than 3 days 
after onset of herpes zoster also demonstrated some decrease 
in new lesion formation. 
INTERFERONS 
Clinical trials with interferons have greatly expanded with 
the increasing supply of a variety of preparations suitable for 
human use. Work in this area has been facilitated by use of 
recombinant DNA technology, by means of which chemically 
homogeneous, high-purity interferon species can be produced 
in quantity. Most likely, these will gradually replace the par­
tially purified buffy coat-derived material used in most clinical 
studies to date. Molecular characterization of the different 
classes of interferons and increased understanding of the mech­
anisms of interferon action have also increased the sophistica­
tion of clinical work with these substances. Current trials are 
exploring the utility of interferons in antineoplastic as well as 
antiviral therapy. Clinical use of interferon remains experimen­
tal; more work will be needed before any preparation can be 
released for general use. 
Most of the clinical experience so far has been with alpha 
(leukocyte) interferon. It consists of over 20 subtypes (molec­
ular species) of proteins that are closely homologous in amino 
acid sequence. Interferon induced in buffy coat leukocytes is a 
mixture of these subtypes, with a2 being the most abundant. 
The a2 subtype has been produced with recombinant DNA 
technology and used in several clinical trials to date. Alpha 
interferon may be given intramuscularly or subcutaneously and 
is suitable for outpatient therapy. All interferons, including the 
recombinant DNA preparations, are associated with adverse 
effects, such as fever, malaise, nausea, anorexia, weight loss, 
bone marrow suppression, and mild hair loss. Bone marrow 
suppression generally reverses rapidly after discontinuing in­
terferon. 
Beta (fibroblast) interferon can be produced in cultures of 
fibroblasts that have been exposed to synthetic interferon 
inducers, but it is now also produced by recombinant DNA 
methods. The amino acid sequences of (I' and {3 interferons 
share a partial homology; naturally occurring {3 interferon is 
typically glycosylated. Natural beta interferon does not give 
effective blood levels following intramuscular administration 
and has to be given intravenously. 
Gamma ("immune," "type II") interferon is produced by T 
cells in response to mitogens or specific antigens. Clinical 
experience with 'Y interferon is currently quite limited, but 
there is great interest in its use because its molecular and 
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biological properties are significantly different from those of a 
and {3 interferons. The biological activities of 'Y interferon 
overlap those of lymphokines such as inter leu kin 2; these latter 
substances are immunomodulators that influence host-virus 
interaction and thus the clinical course of viral infection. 
With the tools of molecular biology it is possible to create 
new species of interferons with amino acid sequences different 
from any known natural interferons. Some of these novel 
interferons may have desirable properties that represent an 
improvement over the natural product, e.g., greater stability, 
better absorption, or more potent antiviral activity. This is 
analogous to the situation with semisynthetic penicillin anti· 
biotics, and it can be anticipated that there will be similarly 
intense activity with antivirals in the future as there currently 
is with antibiotics. Of course, each new interferon preparation 
will require its own set of controlled trials to demonstrate 
clinical efficacy. 
Varicella-Zoster Infections 
Controlled trials with buffy coat alpha interferon in the 
treatment of varicella-zoster infections in immunocompro· 
mised hosts indicate that the results are similar to those ob­
tained with vidarabine and acyclovir. Again, early institution 
of antiviral therapy was important, and all patients were en· 
rolled within 72 h of onset of disease. In varicella [16], inter· 
feron reduced the duration of new vesicle formation, and there 
was less visceral dissemination (none of 21 interferon recipients 
vs 3 of 18 placebo recipients), although the latter finding was 
not statistically significant because of the small patient sample. 
In herpes zoster [17], 1 week of interferon at 5 X 105 units/kg/ 
day accelerated cutaneous healing and decreased cutaneous and 
visceral disseminaiton as well as postherpetic neuralgia. 
Prophylaxis of Herpesvirus Infections in High-Risk Patients 
Animal studies suggest that interferon has the most impact 
on viral infection when given prophylactically. Hence con­
trolled clinical trials have explored the utility of buffy coat 
alpha interferon in the prophylaxis of herpes group virus infec· 
ti(ms in patients known to be at high risk of developing them. 
For example, patients often reactivate herpes simplex labialis 
following surgery of the trigeminal root. Prophylactic interferon 
reduced the rate of reactivation of the virus, as measured by 
virus shedding and/or development of lesions of herpes labialis 
[18]. In renal transplant patients [19], herpes simplex reacti­
vation was not apparently affected, but urinary shedding of 
cytomegalovirus (CMV) was decreased in recipients of prophy­
lactic interferon. Furthermore, prophylaxis reduced the inci­
dence of CMV viremia, as long as the patients did not also 
receive anti thymocyte globulin, a powerful immunosuppressive 
agent. Viremia is generally associated with symptomatic or 
tissue-destructive CMV disease. No clinical benefit was dem­
onstrated in this study; however, a follow-up study restricted 
to transplant patients seropositive for CMV and given greater 
amounts of prophylactic interferon showed that clinical signs 
of CMV infection were reduced in interferon recipients [20]. It 
is important to note that in the latter study, patients received 
less intense immunosuppressive therapy as a group than those 
in the earlier study. The efficacy of interferon may depend on 
the level of immunosuppression in the host. 
Respiratory Viral Infections 
Several studies [21-23] have shown that frequent large doses 
of topical (intranasal) interferon can reduce disease and virus 
shedding following a subsequent challenge dose of rhinovirus. 
Current work has the aim of adapting these findings to a 
regimen that will be clinically acceptable as well as effective. 
Since it is unlikely that healthy individuals will resort to 
frequent nasal sprays in order to prevent a relatively minor 
illness, sustained-release preparations are being studied. 
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TABLE III. Viral infections for which effective therapy is available 
Infection 
Herpes simplex: 
Encephalitis 
Neonatal disease 
Mucocutaneous disease in immu­
nosuppressed hosts 
Genital disease, primary 
Keratit is 
Varicella -zoster: 
Disease in immunocompromised 
hosts 
Respiratory viral infection: 
Influenza A, prophylaxis and early 
therapy 
Influenza A and B 
Respiratory syncytial virus infec­
tion in infants 
Therapy 
Vidarabine, i.v. 
Vidarabine, i.v. 
Acyclovir, i.v. and topical 
Acyclovir, i.v. and topical 
Idoxuridine, topical 
Vidarabine, topical 
Trifluridine, topical 
Other topical agents 
Acyclovir, i.v. 
Vidarabine, i.v. 
Interferon (alpha), i.m. 
Amantadine, oral 
Rimantadine, oral 
Ribavirin, aerosol inhalation 
Ribavirin, aerosol inhalation 
CONCLUSIONS AND PROSPECTS 
Clinically useful therapy is now available for some viral 
infections (Table III), and some guiding principles have 
emerged over the past several years. In the future, greater 
emphasis will be placed on specific and rapid viral diagnosis, 
assessment of the immune competence of the host, and early 
institution of therapies proven effective in controlled trials. 
Antiviral drug trials will include close virologic monitoring and 
take into account the host factors that modify outcome in 
natural disease. Surveillance for the emergence of resistant 
viral strains and unexpected drug toxicity will be necessary. 
More research is needed to gain a better understanding of host­
virus interactions so that therapy may be appropriately tar­
geted. Elimination of the herpesvirus latent state, which is 
responsible for recurrent disease, will be a major goal. 
For the present, translating the results of controlled trials 
into practice is not always straightforward. Lack of effective 
means of early diagnosis is an impediment in the management 
of herpes simplex encephalitis and neonatal herpes infections. 
Acyclovir is not a cure for recurrent genital herpes, even though 
the drug can be very helpful in severe primary genital herpes. 
In varicella-zoster infections, it is difficult, because of differ­
ences in study design, to make a comparison assessment of 
vidarabine, acyclovir, and interferon. Also, in this situation, the 
need for antiviral therapy depends on the degree of immuno­
suppression of the patient. With the lack of any simple, reliable 
measure of the level of immunosuppression, it is not easy to 
determine this. No controlled trial so far has addressed the 
issue of treating visceral dissemination in varicella-zoster in­
fection. The answers to some of the current dilemmas will 
become more clear as more experience accumulates and as 
newer approaches to diagnosis and therapy are developed. 
Studies in progress involve a variety of new drugs, modifi­
cations of existing drugs, drug combinations, and the treatment 
of more diverse and challenging viral infections than those 
previously described. 
Newer nucleoside analogues are appearing frequently, and 
some are likely to enter clinical trials soon. These are developed 
with the aim of improving pharmacokinetic properties (e.g., 
water solubility or oral absorption) and broadening the antiviral 
spectrum to include the more "resistant" viruses, such as cy­
tomegalovirus (CMV) and Epstein-Barr virus (EBV). Most of 
the agents of recent interest are selectively metabolized by 
virus-specified enzymes and are expected to have low human 
toxicity. Not surprisingly, some of the drugs in this category 
are slight modifications of acyclovir [24,25], e.g., dihydroxypro­
poxymethylguanine (DHPG), which appears to be more active 
against CMV in vitro than acyclovir itself. Bromovinyldeox­
yuridine (BVDU) is highly active in vitro against varicella­
zoster and herpes simplex type 1 viruses [26], and it also 
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inhibits EBV [27]. It is well absorbed following oral adminis­
tration and is now undergoing clinical study [28]. If successful, 
it would be an important advance in the therapy of varicella­
zoster infections. 
The status of ribavirin, an inosine monophosphate dehydrog­
enase inhibitor and a broad-spectrum antiviral agent in vitro, 
remains unclear, despite years of clinical experimentation, be­
cause of conflicting data. For example, oral ribavirin was inef­
fective in a controlled trial in treating influenza A [29]. More 
recently, aerosolized ribavirin administered via inhalation was 
shown in randomized trials to be clinically beneficial in the 
treatment of influenza A [30], influenza B [31], and in respi­
ratory syncytical virus infection in infants [32]. Possibly this 
mode of therapy can provide an effective antiviral effect in the 
respiratory tract while minimizing the toxicity seen with sys­
temic administration of ribavirin. 
Sodium phosphonoformate is a DNA polymerase inhibitor 
that is active against herpesviruses (including reversible inhi­
bition of CMV and EBV). Animal studies indicate possible 
clinical application in the topical treatment of herpes simplex 
infections [33]. This drug also inhibits the DNA polymerase of 
hepatitis B and similar viruses in vitro, but unfortunately, it 
was found to be inactive against the virus in vivo in the animal 
model of chronic hepatitis seen in woodchucks [34]. 
The substantial morbidity caused by cytomegalovirus and 
chronic hepatitis B infections makes them a continuing focus 
of therapeutic efforts. Although no regimen has been shown to 
be clinically effective so far, alternative approaches are being 
considered using combinations of existing drugs as well as 
newly developed agents. Previous studies with vidarabine 
[35,36], acyclovir [37,38], and interferon [39] in immunosup­
pressed patients with serious CMV infection showed no consist­
ent clinical benefit. Recently, we treated three patients with 
the acquired immune deficiency syndrome (AIDS) who had 
CMV retinitis using high-dose buffy coat alpha interferon 
[40]. In each case there was progression of the retinitis after 
therapy. Since drug combinations such as acyclovir and inter­
feron appear to be synergistic against CMV in vitro [41], 
clinical trials with such combination therapy may be warranted. 
In chronic hepatitis B, either vidarabine or interferon can 
reversibly suppress viral replication as measured by the viral 
DNA polymerase activity in the blood. The combination of 
vidarabine and interfero� may be more effective in clearing the 
blood of hepatitis B virus [42], but it is also more toxic, since 
interferon potentiates the neurotoxicity of vidarabine. A con­
trolled trial is in progress that is studying this problem more 
systematically, using vidarabine monophosphate and interferon 
as the study drugs [43]. 
REFERENCES 
1. Whitley RJ, Soon� SJ, Hirsch MS, Karchmer AW, Dolin R, 
Galasso G, Dunm.ck JK, Alford CA, NIAID Collaborative Study 
Group: Herpes Simplex encephalitis. Vidarabine therapy and 
diagnostic problems. N Engl J Med 304:313-318 1981 
2. Whitley RJ, Nahmias AJ, Soong SJ, Galasso GG, Fleming CL 
Alford CA: Vidarabine therapy of neonatal herpes simplex infec� 
tion. Pediatrics 66:495-501, 1980 
3. Whitley R, Hilty M, Haynes R, Bryson Y, Connor ,ID, Soong S,], 
Alford CA: Vidarabine therapy of varicella in immunosuppressed 
patients. J Pediatr 101: 125-131, 1982 
4. Whitley R.I, Soong SJ, Dolin R, Betts R, Linnemann C, Alford 
CA: Early vidarabine therapy to control the complications of 
herpes zoster in immunosuppressed patients. N Engl J Med 
307:971-975,1982 
5. Elion GB, Furman PA, Fyfe JA, DeMiranda P, Beauchamp L. 
Schaeffer HJ: Selectivity of action of an anti herpetic agent 9-(2-
hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 
74:5716-5720, 1977 
6. Coen DM, Schaffer PA: Two distinct loci confer resistance to 
acycloguanosine in herpes simplex type I. Proc Natl Acad Sci 
USA 77:2265-2269, 1980 
7. Field HJ, Darby G: Pathogenicity in mice of strains of herpes 
simplex virus which are resistant to acyclovir in vit.ro and in 
vivo. Antimicrob Agents Chemother 17:209-216, 1980 
8. Meyers JD, Wade JC, Mitchell CD, Saral R, Lietman PS Durack 
DT, Levin MJ, Segreti AC, Balfour HH: Multicenter c�llabora-
1208 CHOU 
tive trial of intravenous acyclovir for treatment of mucocuta­
neous herpes simplex virus infection in the immunocompromised 
host. Am J Med 73 (Suppl lA):229-235, 1982 
9. Sara I R, Burns WH, Laskin OL, Santos GW, Lietman PS: Acyclo­
vir prophylaxis of herpes simplex virus infections: A randomized 
double-blind, controlled trial in bone marrow transplant recipi­
ents. N Engl J Med 305:63-67, 1981 
10. Corey L, Fife KH, Benedetti JK, Winter CA, Fahnlander A, Connor 
JD, Hintz MA, Holmes KK: Intravenous acyclovir for the treat­
ment of primary genital herpes. Ann Intern Med 98:914-921, 
1983 
1l. Bryson YJ, Dillon M, Lovett M, Acuna G, Taylor S, Cherry JD, 
Johnson BL, Wiesmeier E, Growdon W, Creagh-Kirk T, Keeney 
R: Treatment of first episodes of genital herpes simplex virus 
infection with oral acyclovir. A randomized double-blind con­
trolled trial in normal subjects. N Engl J Med 308:916-921,1983 
12. Corey L, Nahmias AJ, Guinan ME, Benedetti JK, Critchlow CW, 
Holmes KK: A trial of topical acyclovir in genital herpes simplex 
virus infections. N Engl J Med 306:1313-1319, 1982 
13. Nilsen AE, Aasen T, Halsos AM, Kinge BR, Tjotta EAL, Wikstrom 
K, Fiddian AP: Efficacy of oral acyclovir in the treatment of 
initial and recurrent genital herpes. Lancet 2:571-57:3,1982 
14. Prober CG, Kirk LE, Keeney RE: Acyclovir therapy of chickenpox 
in immunosuppressed children-A collaborative study. J Pediatr 
101:622-625, 1982 
15. Balfour HH, Bean B, Laskin OL, Ambinder RF, Meyers ,lD, Wade 
JC, Zaia JA, Aeppli D, Kirk LE, Segreti AC, Keeney RE, Bur­
roughs-Wellcome Collaborative Acyclovir Study Group: Acyclo­
vir halts progression of herpes zoster in immunocompromised 
patients. N Engl J Med 308:1488-1453, 1983 
16. Arvin AM, Kushner JH, Feldman S, Baehner RL, Hammond D, 
Merigan TC: Human leukocyte interferon for the treatment of 
varicella in children with cancer. N Engl J Med 306:761-765, 
1982 
17. Merigan TC, Rand KH, Pollard RB, Abdallah PS, Jordan GW, 
Fried RP: Human leukocyte interferon for the treatment of 
herpes zoster in patients with cancer. N Engl J Med 298:981-
987, 1978 
18. Pazin G.J, Armstrong ,lA, Lam MT, Tarr GC, ./annetta PJ, Ho M: 
Prevention of reactivated herpes simplex infection by human 
leukocyte interferon after operation on the trigeminal root. N 
Engl.J Med :lOl:225-2:,O, 1979 
19. Cheeseman SH, Ruhin RH, Stewart JA, Tolkoff·Rubin NE, Cosimi 
AB, Cantell K, Gilbert .1, Winkle S, Herrin JT, Black PH, 
Russell PS, Hirsch MS: Controlled clinical trial of prophylactic 
human-leukocyte interferon in renal transplantation. N Engl J 
Med 300:1345-1349, 1979 
20. Hirsch MS, Schooley RT, Cosimi AB, Russell PS, Delmonico FL, 
Tolkoff-Rubin NE, Herrin JT, Cantell K, Farrell ML, Rota TR, 
Rubin RH: Effects of interferon-alpha on cytomegalovirus reac­
tivation syndromes in renal-transplant recipients. N Engl .1 Med 
308:1489-149:1,1983 
21. Merigan TC, Reed SE, Hall TS, Tyrrell DAJ: Inhibition of respi­
ratory virus infection by locally applied interferon. Lancet 1 :563-
567,1973 
22. Scott GM, Phillpotts R.J, Wallace J, Gauci CL, Greiner J, Tyrrell 
DA: Prevention of rhinovirus colds by human interferon alpha-
2 from Escherichia coli. Lancet 2:186-188,1982 
23. Scott GM, Phillpotts RJ, Wallace J, Sec her DS, Cantell K, Tyrrell 
DA: Purified interferon as protection against rhinovirus infec­
tion. Br J Med 284:1822-1825,1982 
24. Larsson A, Oberg B, Alenius S, Hagberg CE, Johansson NG, 
Lindborg B, Stening G: 9-(3,4-Dihydroxybutyl)guanine, a new 
inhibitor of herpesvirus multiplication. Antimicrob Agents 
Chemother 23:664-670, 1983 
25. Smee DF, Martin JC, Verheyden JPH, Matthews TR: Anti-her­
pesvirus activity of acyclic nucleoside 9-(l,3-dihydroxy-2-pro-
Vol. 83, No.1 Supplement 
poxymethyl)guanine. Antimicrob Agents Chemother 23:676-682, 
1983 
26. De Clercq E, Descamps EJ, DeSomer P, Barr PJ, Jones AS, Walker 
RT: (E)-5-(2-bromovinyl)-2' -deoxyuridine: A potent and selec­
tive anti-herpes agent. Proc Nat! Acad Sci USA 76:2947-2951, 
1979 
27. Lin JC, Smith MC, Cheng ye, Pagano JS: Epstein-Barr virus: 
Inhibition of replication by three new drugs. Science 221:578-
579, 1983 
28. De Clercq E, Degreef H, Wildiers J, DeJong& G, Drochmans A, 
Descamps J, DeSomer P: Oral (E)-5-(2-bromovinyl)-2' -deoxyu· 
ridine in severe herpes zoster. Br Med J 281:1178, 1980 
29. Smith CB, Charette RP, Fox JP, Cooney MK, Hall CE: Lack of 
effect of oral ribavirin in naturally occurring influenza A virus 
(HIN1) infection. J Infect Dis 141:548-554, 1980 
30. Knight V, McClung HW, Wilson SZ, Waters BK, Quarles JM, 
Cameron RW, Gregg SE, Zerwas JM, Couch RB: Ribavirin 
small-particle aerosol treatment of influenza. Lancet 2:945-949, 
1981 
31. McClung HW, Knight V, Gilbert BE, Wilson SZ, Quarles JM, 
Divine GW: Ribavirin aerosol treatment of influenza B virus 
infection. JAMA 249:2671-2674, 1983 
32. Hall CB, McBride JT, Walsh EE, Bell DM, Gala CL, Hildreth S, 
Ten Eyck LG, Hall WJ: Aerosolized ribavirin treatment of 
infants with respiratory syncytial virus infection. A randomized 
double-blind study. N Engl .1 Med 308:1443-1447, 198:1 
33. Alenius S, Berg M, Broberg F, Eklind K, Lindbord B, Oberg B: 
Therapeutic effects of foscarnet sodium and acyclovir on cuta· 
neous infections due to herpes simplex type 1 in guinea pigs. J 
Infect Dis 145:569-573, 1982 
34. Nordenfelt E, Widell A, Hansson BG, Loefgren B, Moeller-Nielsen 
C, Oberg B: No in vivo effect of trisodium phosphonoformate on 
woodchuck hepatitis virus production. Acta Pathol Microbiol 
Immunol Scand [B] 90:449-451, 1982 
35. Marker SC, Howard RJ, Groth KE, Mastri AR, Simmons RL, 
Balfour HH: A trial of vidarabine for cytomegalovirus infection 
in renal transplant patients. Arch Intern Med 140:1441-1444, 
1980 
36. Pollard RB, Egbert PR, Gallagher JG, Merigan TC: Cytomegalo­
virus retinitis in immunosuppressed hosts. I. Natural history 
and effects of treatment with adenine arabinoside. Ann Intern 
Med 93:655-664, 1980 
37. Balfour HH, Bean B, Mitchell CD, Sachs GW, Boen JR, Edelman 
CK: Acyclovir in immunocompromised patients with cytomega' 
lovirus disease: Am .1 Med 73 (Suppl. 1A):241--248, 1982 
38. Wade JC, Hintz M, McGuffin R, Springmeyer SC, Connor JD, 
Meyers JD: Treatment of cytomegalovirus pneumonia with high· 
dose acyclovir. Am J Med 73 (Suppl. lA):249-256, 1982 
39. Meyers JD, McGuffin RW, Neiman PE, Singer JW, Thomas ED: 
Toxicity and efficacy of human leukocyte interferon for the 
treatment of cytomegalovirus pneumonia after marrow trans· 
plantation. J Infect Dis 141:555-562, 1980 
40. Chou S, Dylewski JS, Gaynon MW, Egbert PR, Merigan TC: Alpha 
interferon administration in cytomegalovirus retinitis. Antimi­
crob Agents Chemother 25:25-28, 1984 
41. Levin MJ, Leary PL: Inhibition of human herpesviruses by com­
binations of acyclovir and human leukocyte interferon. Infect 
Immunol 32:995-999, 1981 
42. Scullard GH, Pollard RB, Smith JL, Sacks SL, Gregory PB, 
Robinson WS, Merigan TC: Antiviral treatment of chronic hep­
atitis B virus infection. 1. Changes in viral markers with inter­
feron combined with adenine arabinoside. J Infect Dis 143:772-
783, 1981 
43. Smith CI, Kitchen LW, Scullard GH, Robinson WS, Gregory PB, 
Merigan TC: Vidarabine monophosphate and human leukocyte 
interferon in chronic hepatitis B infection . .lAMA 247:2261-
2265, 1982 
